Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amorfix makes R&D appointment

This article was originally published in Scrip

Executive Summary

Amorfix Life Sciences, a Canadian theranostics company developing products and diagnostics for misfolded proteins in brain-wasting diseases and cancer, has appointed Dr Robert Gundel vice-president of R&D. He has 25 years' experience in the industry, having worked at Boehringer Ingelheim, Bayer and Arius Research (Roche). Before taking his role with Amorfix, Dr Gundel served as chief scientific officer at Heat Biologics, and before that was vice-president and head of research at Elusys Therapeutics. Last week, Amorfix announced that it was in discussions with potential partners to further develop its amyloid lateral sclerosis programme, which includes antibodies and vaccines for misfolded SOD1 (copper-zinc superocide dismutase), which it has identified, co-located with beta-amyloid, in the brains of patients with Alzheimer's disease (, January 4th, 2010).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts